A phosphotyrosine switch determines the antitumor activity of ERβ

Journal of Clinical Investigation

Volumn 124, Issue 8, 2014, Pages 3378-3390

  Yuan, Bin ^a,b,c   Cheng, Long ^a   Chiang, Huai Chin ^c   Xu, Xiaojie ^a   Han, Yongjian ^a   Su, Hang ^c   Wang, Lingxue ^a   Zhang, Bo ^d   Lin, Jing ^e   Li, Xiaobing ^d   Xie, Xiangyang ^a   Wang, Tao ^d   Tekmal, Rajeshwar R ^c   Curiel, Tyler J ^c   Yuan, Zhi Min ^c,f   Elledge, Richard ^c   Hu, Yanfen ^c   Ye, Qinong ^a,b   Li, Rong ^c  

^a BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

^b DALIAN MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^e CHINESE PLA GENERAL HOSPITAL   (China)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ESTROGEN RECEPTOR BETA; PHOSPHATASE; PHOSPHOTYROSINE; PROTEIN EYA2; UNCLASSIFIED DRUG; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN; EYA2 PROTEIN, HUMAN; MUTANT PROTEIN; NUCLEAR PROTEIN; PROTEIN TYROSINE PHOSPHATASE; RECOMBINANT PROTEIN; SIGNAL PEPTIDE; TUMOR SUPPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; 129 MOUSE; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; CHEMISTRY; GENE SILENCING; GENETICS; MCF 7 CELL LINE; METABOLISM; PATHOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; GENE KNOCKDOWN TECHNIQUES; HETEROGRAFTS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MCF-7 CELLS; MICE; MICE, 129 STRAIN; MUTANT PROTEINS; NUCLEAR PROTEINS; PHOSPHOTYROSINE; PROGNOSIS; PROTEIN TYROSINE PHOSPHATASES; PROTO-ONCOGENE PROTEINS C-ABL; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEINS;

EID: 84905460024     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI74085     Document Type: Article

References (54)

1. Thomas C, Gustafsson JA. The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer. 2011;11(8):597-608.
2. Deroo BJ, Buensuceso AV. Minireview: estrogen receptor-β: mechanistic insights from recent studies. Mol Endocrinol. 2010;24(9):1703-1714.
3. Hartman J, Lindberg K, Morani A, Inzunza J, Strom A, Gustafsson JA. Estrogen receptor β inhibits angiogenesis and growth of T47D breast cancer xenografts. Cancer Res. 2006;66(23):11207-11213.
4. Mak P, Leung YK, Tang WY, Harwood C, Ho SM. Apigenin suppresses cancer cell growth through ERβ. Neoplasia. 2006;8(11):896-904.
5. Hodges-Gallagher L, Valentine CD, El Bader S, Kushner PJ. Estrogen receptor β increases the efficacy of antiestrogens by effects on apoptosis and cell cycling in breast cancer cells. Breast Cancer Res Treat. 2008;109(2):241-250.
6. Thomas C, et al. ERβ1 represses basal breast cancer epithelial to mesenchymal transition by destabilizing EGFR. Breast Cancer Res. 2012;14(6):R148.
7. Nanni S, et al. Endothelial NOS, estrogen receptor β, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer. J Clin Invest. 2009;119(5):1093-1108.
8. Mak P, et al. ERbeta impedes prostate cancer EMT by destabilizing HIF-1α and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading. Cancer Cell. 2010;17(4):319-332.
9. Nakajima Y, et al. Estrogen regulates tumor growth through a nonclassical pathway that includes the transcription factors ERβ and KLF5. Sci Signal. 2011;4(168):ra22.
10. Gallo D, De Stefano I, Grazia Prisco M, Scambia G, Ferrandina G. Estrogen receptor β in cancer: an attractive target for therapy. Curr Pharm Des. 2012;18(19):2734-2757.
11. Marotti JD, Collins LC, Hu R, Tamimi RM. Estrogen receptor-β expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. Mod Pathol. 2010;23(2):197-204.
12. Hanson IM. Mammalian homologues of the Drosophila eye specification genes. Semin Cell Dev Biol. 2001;12(6):475-484.
13. Rayapureddi JP, et al. Eyes absent represents a class of protein tyrosine phosphatases. Nature. 2003;426(6964):295-298.
14. Li X, et al. Eya protein phosphatase activity regulates Six1-Dach-Eya transcriptional effects in mammalian organogenesis. Nature. 2003;426(6964):247- 254.
15. Tootle TL, et al. The transcription factor Eyes absent is a protein tyrosine phosphatase. Nature. 2003;426(6964):299-302.
16. Ohto H, et al. Cooperation of six and eya in activation of their target genes through nuclear translocation of Eya. Mol Cell Biol. 1999;19(10):6815- 6824.
17. Xiong W, Dabbouseh NM, Rebay I. Interactions with the abelson tyrosine kinase reveal compartmentalization of eyes absent function between nucleus and cytoplasm. Dev Cell. 2009;16(2):271-279.
18. Okabe Y, Sano T, Nagata S. Regulation of the innate immune response by threoninephosphatase of Eyes absent. Nature. 2009;460(7254):520-524.
19. Cook PJ, Ju BG, Telese F, Wang X, Glass CK, Rosenfeld MG. Tyrosine dephosphorylation of H2AX modulates apoptosis and survival decisions. Nature. 2009;458(7238):591-596.
20. Krishnan N, et al. Dephosphorylation of the C-terminal tyrosyl residue of the DNA damagerelated histone H2A. X is mediated by the protein phosphatase eyes absent. J Biol Chem. 2009;284(24):16066-16070.
21. Zhang L, et al. Transcriptional coactivator Drosophila eyes absent homologue 2 is up-regulated in epithelial ovarian cancer and promotes tumor growth. Cancer Res. 2005;65(3):925-932.
22. Pandey RN, et al. The Eyes Absent phosphatasetransactivator proteins promote proliferation, transformation, migration, and invasion of tumor cells. Oncogene. 2010;29(25):3715-3722.
23. Farabaugh SM, Micalizzi DS, Jedlicka P, Zhao R, Ford HL. Eya2 is required to mediate the prometastatic functions of Six1 via the induction of TGF-β signaling, epithelial-mesenchymal transition, and cancer stem cell properties. Oncogene. 2012;31(5):552-562.
24. Colicelli J. ABL tyrosine kinases: evolution of function, regulation, and specificity. Sci Signal. 2010;3(139):re6.
25. Hunter T. Treatment for chronic myelogenous leukemia: the long road to imatinib. J Clin Invest. 2007;117(8):2036-2043.
26. Ganguly SS, Plattner R. Activation of abl family kinases in solid tumors. Genes Cancer. 2012;3(5-6):414-425.
27. Srinivasan D, Sims JT, Plattner R. Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorageindependent growth and survival. Oncogene. 2008;27(8):1095-1105.
28. Kiely PA, et al. Phosphorylation of RACK1 on tyrosine 52 by c-ABL is required for insulin-like growth factor I-mediated regulation of focal adhesion kinase. J Biol Chem. 2009;284(30):20263-20274.
29. Noren NK, Foos G, Hauser CA, Pasquale EB. The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway. Nat Cell Biol. 2006;8(8):815-825.
30. Allington TM, Galliher-Beckley AJ, Schiemann WP. Activated Abl kinase inhibits oncogenic transforming growth factor-β signaling and tumorigenesis in mammary tumors. FASEB J. 2009;23(12):4231-4243.
31. Cristofanilli M, et al. Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-β: clinical activity and biological correlations. Ann Oncol. 2008;19(10):1713-1719.
32. Yardley DA, et al. Phase II trial of docetaxal plus imatinib mesylate in the treatment of patients with metastatic breast cancer. Clin Breast Cancer. 2009;9(4):237-242.
33. Tsai KK, Yuan ZM. c-ABL stabilizes p73 by a phosphorylation-augmented interaction. Cancer Res. 2003;63(12):3418-3424.
34. Yang J, et al. Discovery and characterization of a cell-permeable, small-molecule c-ABL kinase activator that binds to the myristoyl binding site. Chem Biol. 2011;18(2):177-186.
35. Stuart JR, Kawai H, Tsai KK, Chuang EY, Yuan ZM. c-ABL regulates early growth response protein (EGR1) in response to oxidative stress. Oncogene. 2005;24(55):8085-8092.
36. Ohtake F, et al. Modulation of oestrogen receptor signalling by association with the activated dioxin receptor. Nature. 2003;423(6939):545-550.
37. Bouchal J, Santer FR, Hoschele PP, Tomastikova E, Neuwirt H, Culig Z. Transcriptional coactivators p300 and CBP stimulate estrogen receptor-β signaling and regulate cellular events in prostate cancer. Prostate. 2011;71(4):431-437.
38. Metivier R, et al. Estrogen receptor-a directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell. 2003;115(6):751-763.
39. Cheng L, et al. PES1 promotes breast cancer by differentially regulating ERα and ERβ. J Clin Invest. 2012;122(8):2857-2870.
40. Allington TM, Schiemann WP. The Cain and Abl of epithelial-mesenchymal transition and transforming growth factor-β in mammary epithelial cells. Cells Tissues Organs. 2011;193(1-2):98-113.
41. Tremblay GB, et al. Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor β. Mol Endocrinol. 1997;11(3):353-365.
42. Tremblay A, Tremblay GB, Labrie F, Giguere V. Ligand-independent recruitment of SRC-1 to estrogen receptor β through phosphorylation of activation function AF-1. Mol Cell. 1999;3(4):513-519.
43. Picard N, et al. Phosphorylation of activation function-1 regulates proteasome-dependent nuclear mobility and E6-associated protein ubiquitin ligase recruitment to the estrogen receptor β. Mol Endocrinol. 2008;22(2):317-330.
44. Sanchez M, Picard N, Sauve K, Tremblay A. Challenging estrogen receptor β with phosphorylation. Trends Endocrinol Metab. 2010;21(2):104-110.
45. Lam HM, et al. Phosphorylation of human estrogen receptor-beta at serine 105 inhibits breast cancer cell migration and invasion. Mol Cell Endocrinol. 2012;358(1):27-35.
46. Jackson RL, Greiwe JS, Schwen RJ. Emerging evidence of the health benefits of S-equol, an estrogen receptor β agonist. Nutr Rev. 2011;69(8):432-448.
47. Ishiwata N, Melby MK, Mizuno S, Watanabe S. New equol supplement for relieving menopausal symptoms: randomized, placebocontrolled trial of Japanese women. Menopause. 2009;16(1):141-148.
48. Krueger AB, et al. Identification of a selective small-molecule inhibitor series targeting the eyes absent 2 (Eya2) phosphatase activity. J Biomol Screen. 2012;18(1):85-96.
49. Zhang H, et al. Stimulatory cross-talk between NFAT3 and estrogen receptor in breast cancer cells. J Biol Chem. 2005;280(52):43188-43197.
50. Secreto FJ, Monroe DG, Dutta S, Ingle JN, Spelsberg TC. Estrogen receptor α/β isoforms, but not betacx, modulate unique patterns of gene expression and cell proliferation in Hs578T cells. J Cell Biochem. 2007;101(5):1125-1147.
51. Aiyar SE, et al. Attenuation of estrogen receptor α-mediated transcription through estrogenstimulated recruitment of a negative elongation factor. Genes Dev. 2004;18(17):2134-2146.
52. Hu Y-F, Miyake T, Ye Q, Li R. Characterization of a novel trans-activation domain of BRCA1 that functions in concert with the BRCA1 C-terminal (BRCT) domain. J Biol Chem. 2000;275(52):40910-40915.
53. Ding N, et al. Mediator links epigenetic silencing of neuronal gene expression with x-linked mental retardation. Mol Cell. 2008;31(3):347-359.
54. Ding L, et al. Human four-and-a-half LIM family members suppress tumor cell growth through a TGF-β-like signaling pathway. J Clin Invest. 2009;119(2):349-361.